These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32832095)

  • 1. Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin-an epidemiological surveillance study using Japanese large health insurance claims database.
    Imai S; Momo K; Kashiwagi H; Miyai T; Sugawara M; Takekuma Y
    J Pharm Health Care Sci; 2020; 6():18. PubMed ID: 32832095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Evaluation of Pharmacist Interventions in Patients Treated with Anti-methicillin-Resistant Staphylococcus aureus Agents in a Hematological Ward.
    Okada N; Fushitani S; Azuma M; Nakamura S; Nakamura T; Teraoka K; Watanabe H; Abe M; Kawazoe K; Ishizawa K
    Biol Pharm Bull; 2016; 39(2):295-300. PubMed ID: 26830489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination effect of arbekacin and cefepime on mixed culture of MRSA and P. aeruginosa].
    Araake M; Hara T; Miyata A; Tani M; Ogawa H
    Jpn J Antibiot; 2001 Feb; 54(2):69-78. PubMed ID: 11338680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of trends and factors associated with therapeutic drug monitoring (TDM) implementation for arbekacin treatment using a large Japanese medical claims database.
    Ito S; Goto R; Inose R; Kusama Y; Ono A; Koizumi R; Ishikane M; Ohmagari N; Muraki Y
    J Infect Chemother; 2022 Sep; 28(9):1266-1272. PubMed ID: 35606308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of arbekacin on the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus].
    Miyata A; Araake M; Ogawa H; Hanaki H; Hiramatsu K
    Jpn J Antibiot; 2001 Jul; 54(7):372-81. PubMed ID: 11560056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug sensitivity and teicoplanin resistance of coagulase-negative Staphylococcus isolated from blood culture].
    Nakamura T; Takahashi H
    Kansenshogaku Zasshi; 2004 Jan; 78(1):46-53. PubMed ID: 15103893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
    Sazanami K; Inose R; Yagi T; Dote S; Horiuchi N; Kobayashi Y; Muraki Y
    J Infect Chemother; 2021 Dec; 27(12):1723-1728. PubMed ID: 34446352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reliability of disc-diffusion susceptibility testing for arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus].
    Kouda M; Homma S; Udagawa I; Tamura K; Fukuhara J; Takeuchi M
    Jpn J Antibiot; 1999 Dec; 52(12):681-9. PubMed ID: 10695023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of pharmacists and infection control teams or antimicrobial stewardship teams on the safety and efficacy of vancomycin: A Japanese administrative claims database study.
    Goto R; Muraki Y; Inose R; Kusama Y; Ono A; Koizumi R; Ishikane M; Ohmagari N
    PLoS One; 2022; 17(9):e0274324. PubMed ID: 36083990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of breakthrough Gram-positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation.
    Ohata K; Kitagawa J; Niwa T; Takahashi-Yamauchi T; Harada S; Matsumoto T; Nakamura N; Nakamura H; Kanemura N; Shimizu M; Suzuki A
    J Clin Pharm Ther; 2020 Dec; 45(6):1342-1348. PubMed ID: 32656902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database.
    Goto R; Muraki Y; Inose R; Ichii M; Sawada K; Mizuno K; Koizumi R; Tsuzuki S; Ishikane M; Ohmagari N
    J Pharm Health Care Sci; 2023 Nov; 9(1):35. PubMed ID: 37908001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011.
    Shigemura K; Osawa K; Mukai A; Yoshida H; Fujisawa M; Arakawa S
    J Antibiot (Tokyo); 2013 May; 66(5):273-6. PubMed ID: 23531989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice.
    Kaneko Y; Yanagihara K; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3694-8. PubMed ID: 14638467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model.
    Hussain K; Ikram R; Ambreen G; Salat MS
    J Pharm Policy Pract; 2021 Nov; 14(1):100. PubMed ID: 34847951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro].
    Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K
    Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)].
    Hatano K; Yokota Y; Hanaki H; Sunakawa K
    Kansenshogaku Zasshi; 2006 May; 80(3):243-50. PubMed ID: 16780131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends of the Use of Anti-methicillin-Resistant Staphylococcus aureus Agents in Japan Based on Sales Data from 2006 to 2015.
    Goto R; Inose R; Kusama Y; Kawabe A; Ishii S; Ebisui A; Ishikane M; Yagi T; Ohmagari N; Muraki Y
    Biol Pharm Bull; 2020; 43(12):1906-1910. PubMed ID: 33268708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination effect of pazufloxacin and anti-mrsa drugs against beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)].
    Yanagisawa C; Hanaki H; Oishi T; Uehara K; Yamaguchi Y; Matui H; Sunakawa K
    Jpn J Antibiot; 2005 Feb; 58(1):11-6. PubMed ID: 15847221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus.
    Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y
    J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacteriological activities of arbekacin and vancomycin against strains of MRSA].
    Ishii T; Takayama Y; Takase Y; Orikasa Y
    Jpn J Antibiot; 1994 Jun; 47(6):647-54. PubMed ID: 8072173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.